Business Strategy

At Nastech, we are focused on expanding our capabilities as an integrated pharmaceutical company in order to develop and commercialize new and improved pharmaceutical products. We will continue to advance our existing core technologies and know-how in areas such as tight junction biology, formulation science and nasal drug delivery. We will also invest in new technologies that will be necessary to produce safer and more effective pharmaceuticals. Our manufacturing expertise and expansion of our commercial operations will allow us to capture a greater share of the downstream value that we create through our partnerships and independent programs.

Quick Facts

Locations:		Headquarters: Bothell, WA Manufacturing Facility: Hauppauge, NY
Stock Information:		NSTK (Nasdaq)
Number of Employees:		Approximately 87

Product Pipeline

Lead programs include: PTH_1-34 for osteoporosis in Phase 2 trials; Peptide YY_3-36 for obesity in Phase 2 trials; Exenatide for type II diabetes in Phase 1 trials; and Calcitonin for osteoporosis, with an ANDA filed with the U.S. Food and Drug Administration. View our product pipeline for a complete list of our programs in development.

Research & Development

Nastech is a leader in drug delivery technologies that focus on the regulation and manipulation of tight junction biology. Tight junctions are cell-to-cell connections that regulate the transport and passage of therapeutic drugs. Nastech also has expertise in pharmaceutical formulation science, a systematic approach to drug development designed to maximize therapeutic efficacy and safety. Nastech is at the leading edge of the breakthrough technology of RNA interference (RNAi), using it both as a research tool to study tight junctions and also examining its potential as a therapeutic product.

Nastech's core technical competency in molecular-biology based drug delivery involves the research, development and manufacture of nasally administered prescription pharmaceuticals. Nastech's nasal drug delivery technology has demonstrated value in designing optimized, customizable dosage forms and in delivering peptides and complex protein drugs that can currently only be delivered by injection or other less desirable routes.

Manufacturing

Nastech has invested in the people and technology crucial to manufacturing pharmaceuticals within the industry's tightly regulated environment. Our advanced manufacturing facilities provide the capacity and qualifications necessary to consistently produce high quality pharmaceutical products. We view manufacturing as an important component to our financial bottom line and believe that it is a critical component of Nastech's value to our partners.

Partnerships

Nastech is engaging in collaborations that will enable both parties to rapidly develop and commercialize therapeutics by leveraging their respective technologies and capabilities. We also place a high value on relationships that will provide us the opportunity to expand our internal research and development programs through access to new technologies and early stage compounds.

Employees

Nastech's employees are dedicated to the development and application of innovative science and technologies. Nastech's exciting science and development programs have enabled us to attract experts in molecular biology, chemistry, pharmacology, manufacturing and quality control as well as a very experienced pharmaceutical management team.